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Introduction: Recent clinical trials have shown significant survival
benefits from postoperative adjuvant therapy for respectable non-
small cell lung cancer (NSCLC). However, evaluation of adjuvant
chemotherapy with carboplatin combination is still uncertain. The
purpose of the study was to test the feasibility of adjuvant chemo-
therapy with carboplatin and separate weekly paclitaxel after com-
plete resection of pStage IB, II, IIIA NSCLC in a multicenter study.
Methods: The study was conducted from 2001 to 2006 in the
outpatient setting. A total of 61 patients were enrolled. Patients
received adjuvant chemotherapy with 4 cycles of carboplatin (AUC
5) on day 1 and paclitaxel (70 mg/m2) on day 1, 8, and 15 every 4
weeks. Primary endpoints were toxicity and chemotherapy compli-
ance. Secondary endpoints were disease-free survival and overall
survival.
Results: More than 65% of eligible patients had pStage IIIA. The
median number of chemotherapy cycles was 4 (range 1–4). Grade 3
or 4 toxicities of neutropenia were 34% (grade 4: 2%). Other
hematologic adverse effects were extremely less frequent. Regard-
ing the nonhematologic adverse effect, hair loss was frequent;
however, peripheral neuralgia was less frequent. Treatment-related
death was not registered. During median follow-up of 21 months, 24
patients developed recurrent disease. Estimated disease-free survival
and overall survival at 2 years was 51.2% and 84.6%, respectively.
Conclusions: Postoperative carboplatin and weekly paclitaxel
showed favorable feasibility and acceptable toxicity in comparison
with the cisplatin-containing regimen. Consequently, it is desirable
that this regimen would be validated in a phase III clinical trial for
NSCLC after curative resection.
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(J Thorac Oncol. 2008;3: 612–616)
Recent advances in postoperative chemotherapy results in abetter prognosis for completely resected stage II–IIIA
nonsmall cell lung cancer (NSCLC). Platinum doublet, espe-
cially vinorelbine plus cisplatin, is recommended in the
NCCN Clinical Practice Guidelines.1 However, paclitaxel
plus carboplatin regimen is widely used even for postopera-
tive cases because of better compliance due to the experience
of less toxicity for stage IIIB, IV NSCLC. Therefore, it is
necessary to establish adjuvant use of paclitaxel plus carbo-
platin although negative results were unexpectedly reported
in the additional analysis by CALGB 9633.2,3 Weekly admin-
istration of paclitaxel is reported in the literature to be less
toxic compared with monthly use.4 We conducted a multi-
center trial with weekly administration of paclitaxel plus a
carboplatin regimen to assess feasibility and toxicity.
PATIENTS AND METHODS
Eligibility
Patients were eligible for the main trial if they fulfilled
the following local criteria for pathologic diagnosis of Stage
IB, II, IIIA NSCLC5 after curative lobectomy and systematic
mediastinal lymphadenectomy: age 20–75 years; Eastern
Cooperative Oncology Group performance status of 0, 1 or 2;
neutrophil count greater than 1500 mm3 and a platelet count
greater than 100,000 mm3; serum bilirubin level less than
1.5 mg/dl; AST and ALT levels equal to or less than 2 times
the institutional normal; and creatinine less than 1.5 mg/dl.
Patients were ineligible if they had concurrent malignancy or
a history of malignancy, uncontrollable complications, severe
postoperative morbidity, previous treatment other than sur-
gery, hypersensitivity to agents containing polyoxyethylene
caster oil or preparations containing sclerosing caster oil, the
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possibility of being pregnant, and other conditions as judged
by the attending physician.
Treatment and Trial Design
This was a multicenter prospective study of feasibility.
Postoperative chemotherapy consisted of treatment with car-
boplatin (AUC 5 on day 1) and paclitaxel (70 mg/m2 on days
1, 8, and 15) for a total of 4 cycles. Calvert’s formula was
used to calculate the dose of the area under the curve (AUC)
for carboplatin,6 whereas the creatinine clearance was deter-
mined with the formula by Jelliffe.7 It was started within one
month after surgery mainly in the outpatient setting. Courses
were repeated every 4 weeks. Complete blood cell counts
were measured before the beginning of a new course. Treat-
ment would delayed 1 week if the neutrophil count was less
than 1000 mm3, the platelets were less than 50,000 mm3,
or peripheral neuralgia was grade 3 or 4. If these conditions
were not resolved within 3 weeks, the patient was withdrawn.
Paclitaxel was reduced to 60 mg/m2 for febrile leucocytope-
nia, a neutrophil count less than 500 mm3, grade 2 periph-
eral neuropathy, and grade 3 nonhematologic toxicity. Car-
boplatin was also reduced to AUC 4 for a neutrophil count
less than 500 mm3, platelets less than 50000 mm3, creat-
inine greater than 1.5 times the upper normal limit, and grade
3 nonhematologic toxicity. The maximum grade on the NCI
Common Toxicity Criteria for Adverse Events (version 2.0)
was reported for hematological and nonhematological toxic
effects. Neuropathy includes peripheral neuritis, neuritis,
neuropathy, and paresthesia.
In case patients experienced a relapse, it was with-
drawn. The choice of any subsequent treatment depended on
the institute.
Ethics
The Ethics Committee in each participating hospital
approved the protocol, and written informed consent was
obtained from each patient.
Observations and Evaluations
Primary endpoints were to assess adverse effects and
compliance with the chemotherapy protocols. Secondary end-
points were disease-free survival and overall survival, which
were calculated with the Kaplan-Meier method, whereas the
log-rank test was used to compare the curves. Both survival
analyses were performed by intent-to-treat.
RESULTS
Between April 2001 and May 2006, 61 patients were
enrolled in the feasibility study. Patient characteristics are shown
in Table 1. Patients with Stage IIIA with N2 positive lymph
node metastasis consisted of 41 cases (67%). Adenocarcinoma
was observed in 43 cases (70%). None of the patients received
induction or postoperative radiotherapy.
Toxicity
Regarding hematological toxicity, grade 3/4 leucocyto-
penia and neutropenia were observed in 8.2% and 36.1%,
respectively (Table 2). Of these patients, grade 4 leucocyto-
penia was not observed, and grade 4 neutropenia was found
in only 1 case (1.6%). Grade 3 thrombocytopenia was ob-
served in only 2 cases (3.3%). Grade 3/4 decreased hemo-
globin was observed in 4 cases (6.6%).
Regarding nonhematological toxicity, grade 1/2 alope-
cia was seen most frequently with 53 cases (87%). Grade 3/4
gastrointestinal toxicity (nausea/vomiting/appetite loss) was
observed in 1/0/5 cases, respectively (Table 2). Grade 1/2/3/4
peripheral neuropathy was observed in 11/4/1/0 cases (18%/
6.6%/1.6%/0%). Other nonhematological toxic effects were
shown in Table 2. Treatment-related death was not registered.
Chemotherapy Compliance
Chemotherapy compliance in over 3 courses and 4
courses were 75.4% and 68.9%, respectively (Table 3). Out
of 42 cases that completed 4 cycles, 36 cases (85.7%) did not
reduce the initial dose as shown in table 3. The reasons some
patients did not complete 4 cycles were rejection in 7 cases,
hematological toxicity in 6 cases, and liver dysfunction in 2
cases (Table 4).
Disease-Free Survival and Overall Survival (Fig. 1)
(Fig. 2)
Median follow-up time was 21 months. The two-year
disease-free survival rate was 51.2%, and the two-year over-
all survival rate was 84.6%. Pathologic stage and conditions
of recurrence were shown in Table 5. There is not significant
relationship between pathologic stage and type of recurrence.
TABLE 1. Patient Characteristics
(%)
Median age (range) 62 (38–75)
Registered patients 61
Gender (male/female) 42/19
Pathological stage
IB 7 (11.5)
T2N0 7
IIA 8 (13.1)
T1N1 8
IIB 5 (8.2)
T3N0 2
T2N1 3
IIIA 41 (67.2)
T3N1 3
T1N2 18
T2N2 18
T3N2 2
Histologic features
Adenocarcinoma 43 (70.5)
Squamous dell carcinoma 12 (19.7)
Large cell carcinoma 1 (1.6)
Mixed 3 (4.5)
Other* 1 (1.6)
ECOG performance status
0 48 (78.7)
1 12 (19.7)
2 1 (1.6)
*Lymphoepithelioma-like carcinoma.
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DISCUSSION
According to recent advances in postoperative adjuvant
therapy, a vinorelbine and cisplatin regimen improved overall
survival in patients with stages II to IIIA NSCLC. NCCN
Clinical Practice Guidelines in Oncology recommend this
regimen in category 2A.1 However, it is not sufficiently
useful to administer cisplatin in the outpatient setting because
cisplatin requires hydration to prevent renal toxicity from
unsatisfactory compliance as a serious clinical problem. On
the contrary, CALGB once reported significantly better sur-
vival in postoperative administration of carboplatin (AUC 6)
and monthly paclitaxel (200 mg/m2) for stage IB NSCLC;
however, the significance turned out to be negative probably
because study did not have power enough to detect small
differences in overall survival. However, failure-free survival
was still significant and better compliance of carboplatin
comparing cisplatin was also emphasized.2,3 Among the an-
ticancer drugs for far-advanced lung cancer, carboplatin is
more favorable because of less toxicity in the outpatient
setting. In fact, practical use of carboplatin and paclitaxel are
also the most popular adjuvant regimen even in patients with
completely resected NSCLC without confirmed evidence.
In a phase I study for chemotherapy-naive patients with
stage IIIB/IV NSCLC, the recommended dose for a weekly
paclitaxel and carboplatin combination regimen should be
paclitaxel 70 mg/m2 on days 1, 8, 15 plus carboplatin AUC 6
on day 1 of a 4 week cycle.8 Increasing the single-agent
TABLE 2. Worst Adverse Event by NCI Grading (NCI-CTC Version 2)
(%) Grade 0 Grade 1 Grade 2 Grade 3 Grade 4
Leucocytopenia 15 (24.6) 17 (27.9) 24 (39.3) 5 (8.2) 0
Neutropenia 10 (16.4) 5 (8.2) 24 (39.3) 20 (32.8) 2 (3.3)
Thrombocytopenia 51 (83.6) 8 (13.1) 1 (1.6) 1 (1.6) 0
Anemia 17 (27.9) 21 (34.4) 9 (31.1) 3 (4.9) 1 (1.6)
Febrile neutropenia 59 (96.7) 0 0 2 (3.3) 0
Fatigue 24 (39.3) 29 (47.5) 7 (11.5) 1 (1.6) 0
Infection 57 (93.4) 0 1 (1.6) 3 (4.5) 0
Gastrointestinal
Stomatitis 56 (91.8) 5 (8.2) 0 0 0
Appetite loss 17 (27.9) 27 (44.3) 12 (19.7) 5 (8.2) 0
Nausea 30 (49.2) 22 (36.1) 8 (13.1) 1 (1.6) 0
Vomiting 50 (82.0) 6 (9.8) 5 (8.2) 0 0
Diarrhea 53 (86.9) 6 (9.8) 0 2 (3.3) 0
Constipation 55 (90.2) 5 (8.2) 1 (1.6) 0 0
Neuropathy 45 (73.8) 11 (18.0) 4 (6.6) 1 (1.6) 0
Alopecia 8 (13.1) 13 (21.3) 40 (65.6) — —
Rash 52 (85.2) 7 (11.5) 2 (3.3) 0 0
Pain (muscle, joint) 52 (85.2) 6 (9.8) 1 (1.6) 2 (3.3) 0
Pneumonitis 59 (96.7) 2 (3.3) 0 0 0
Allergic reaction 59 (96.7) 1 (1.6) 0 1 (1.6) 0
Laboratory 49 (80.3) 10 (16.4) 2 (3.3) 0 0
AST elevation 40 (65.6) 14 (23.0) 6 (9.8) 1 (1.6) 0
ALT elevation 51 (83.6) 8 (13.1) 2 (3.3) 0
Bilirubin elevation 55 (90.2) 6 (9.8) 0 0 0
Albumin low 46 (75.4) 14 (23.0) 1 (1.6) 0 0
Abbreviation: NCI-CTC National Cancer Institute common toxicity criteria version 2.
TABLE 3. Chemotherapy Compliance
No. of Cycles
Number of Patients (%)
1 2 3 4
Completed patients 59 (96.7) 53 (86.9) 46 (75.4) 42 (68.9)
Drug off (postponement) 6 (10) 17 (32) 13 (28) 15 (36)
Dose reduction 1 (2) 4 (8) 7 (15) 6 (14)
TABLE 4. Reasons for Discontinuation
No of Patients (%)
Patient rejection 7 (11.5)
Hematologic toxicity 6 (9.8)
Liver dysfunction 2 (3.3)
Gastrointestinal toxicity 3 (4.5)
Allergy 1 (1.6)
Cancer recurrence 1 (1.6)
Surgical complications 1 (1.6)*
Pneumonia 1 (1.6)
Others 3 (4.5)
*Bronchial fistula.
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carboplatin AUC above 5 to 7 mg/ml did not improve the
likelihood of a response but did increase myelotoxicity in
1,028 ovarian cancer patients.9 In a phase I study of a weekly
single-agent paclitaxel administered once per week for 3
weeks every 4 weeks, 80 mg/m2 /wk is a better safety margin
as the phase II dose for patients with recurrent or metastatic
NSCLC.10 Therefore, carboplatin (AUC 5 on day 1) and
paclitaxel (70 mg/m2 on 1, 8, and 15) was determined for
adjuvant setting study by reducing the carboplatin dose for
safety. Mean dose intensity of paclitaxel was 52 mg/m2/wk in
our regimen for outpatient, which was 210 mg/m2/mo.
The main limitation of this study is the few number of
the patients enrolled, and the short follow-up. The main
reason for low recruitment and high percentage of stage IIIA
was in favor of UFT for patients with stage IB. Most of the
patients with stage IB were not unfortunately enrolled in the
study during the period because UFT is considered as stan-
dard adjuvant regimen for completely resected stage IB-
disease at present in Japan.11 However, it should be empha-
sized that the primary end point of the study is to assess
feasibility of the new adjuvant regimen, especially toxicity
and chemotherapy compliance. The results of less toxicity
and better compliance of carboplatin and weekly paclitaxel
regimen is necessary to employ reference arm for upcoming
randomized clinical trial.
Hematological toxicity was significantly less compared
with the other regimen, especially grade 3/4 neutropenia, in
which our regimen induced 36.1% in which grade 4 neutro-
penia was observed in only 2 cases (3.3%). In the JBR 10
study and ANITA study, cisplatin and vinorelbine adminis-
tration induced grade 3/4 neutropenia in 73% and 85%, and
grade 4 neutropenia seemed to be frequently observed.12,13
Rosenberg, et al reported that grade 3–4 hematological and
nonhematological toxicity occurred more frequently in a
paclitaxel regimen of every 3 weeks (200 mg/m2) compared
with a weekly regimen (67 mg/m2) under the same delivered
dose intensity.14 Socimski et al also indicated that grade 4
neutropenia was reduced in weekly paclitaxel regmen.4
Thrombocytopenia, which is DLT of carboplatin, was ob-
served grade 3/4 in only 1/none cases (1.6/0%) in our series
Pr
ob
ab
ili
ty
 o
f D
is
ea
se
-F
re
e 
Su
rv
iv
al
 (%
)
0
10
20
30
40
50
60
70
80
90
100
0 365 730 1095 1460 1825 2190
Times after surgery (days)
FIGURE 1. Disease-free survival curves using
the Kaplan-Meier method. Analysis was by in-
tention to treat. Censored cases are shown by
crosses. The two-year disease-free survival rate
was 51.2%.
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FIGURE 2. Overall survival curves using the
Kaplan-Meier method. Analysis was by inten-
tion to treat. Censored cases are shown by
crosses. The two-year overall survival rate was
84.6%.
TABLE 5. Pathological Stage and Type of Recurrence
Pathological
Stage
No. of
Cases
No. of
Recurrent
Cases Local
(%)
Systemic
IB 7 1 (14.3) 1 0
IIA 8 3 (37.5) 2 1
IIB 5 2 (40.0) 1 1
IIIA 41 17 (41.5) 6 11
Total 61 23 (37.7) 10 (16.4) 13 (21.3)
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thus sparing patients the effect of paclitaxel.15–17 Nonhema-
tologic toxicity hair loss occurred frequently in 86.9%; in
contrast peripheral neuralgia was less in comparisons of the
monthly paclitaxel regimen. Rosenberg, et al also indicated
that weekly paclitaxel administration resulted in less neurop-
athy than administration with every 3 weeks between the
same dose-intensity of paclitaxel in a randomized study.14 In
fact, severe neuropathy observes more frequently with over
250 mg/m2 administration dose than that below 200 mg/m2.18
Regarding treatment-related deaths, 2 (0.8%) in the JBR10
and 7 patients (2%) in the ANITA trial died compared with
none in our study.12,13 Compliance with the chemotherapy
protocol was excellent in our regimen comparing cisplatin
plus vinorelbine for adjuvant setting of NSCLC with 75.5%/
68.9% in 3/4 cycles of completed cases, while compliance
was 58%/48% in the JBR10 and 61/50% in ANITA trials.12,13
The data of the survival is still preliminary and must be
followed. Howevwer, the overall survival rate was not poor at
2 years although our series contained pStage IIIA at 67%.2,3
In the subgroup analysis in pathologic Stage IIIA, our results
showed a better prognosis compared with Mountain’s report.5
Belani et al indicated that standard weekly schedule of
paclitaxel (100 mg/m2) and carboplatin (AUC6 on day1)
achieved the goal of favorable efficacy with a highly tolerable
toxicity profile in comparison with the results of other two
regimens with weekly paclitaxel and weekly carboplatin
(AUC2).19
Feasibility of carboplatin and weekly paclitaxel was
confirmed as a promising adjuvant schedule for completely
resected NSCLC. This regimen was expected to be the
reference arm of a phase III study compared with cisplatin
and vinorelbine as the control arm.
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